Predicting Mutational Signature Exposures from H&E Whole Slide Images: A Pan-Cancer Feasibility Study
Mutational signatures reveal cancer-driving processes with clinical relevance: MMR-deficient tumors respond better to immunotherapy, HRD tumors are sensitive to PARP inhibitors, and POLE-mutant tumors often have high mutation burdens influencing treatment response. Yet signature profiling remains limited by the cost, c...